RxDoctor Payments Data

Erin Nulf, PA

Physician Assistant · Spokane Valley, WANPI 1164692950

Payments from drug & device makers

$5,396in general payments, 2019–2025

Across 109 payments — averaging $49.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • UCB, Inc.$844
  • AbbVie$775
  • E.r. Squibb & Sons, L.L.C.$569
  • Lilly USA, LLC$220
  • Novartis$181
  • plus $587 from 8 others

What the payments were for

  • Consulting fees$1,06320%
  • Food & beverage$4,06575%
  • Education$2685%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,396 in reported general payments places this provider in the 95th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$190,519
Medicare patients
538
Services billed
3,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast21$111,192
Tretinoin38$2,431
Fluorouracil30$2,222
Clindamycin Phosphate43$1,753
Tacrolimus15$1,587
Mycophenolate Mofetil18$1,577
Clobetasol Propionate34$1,515
Doxycycline Monohydrate41$1,360
Triamcinolone Acetonide99$1,328
Ketoconazole91$1,144
ValacyclovirValacyclovir Hcl28$1,109
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc22$1,024
Hydroxychloroquine Sulfate20$991
Minocycline Hcl22$904
Minoxidil67$849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$40$111,19221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Spokane Valley

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →